Premium
Treatment of vulval Crohn's disease with infliximab
Author(s) -
Preston P. W.,
Hudson N.,
Lewis F. M.
Publication year - 2006
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2006.02079.x
Subject(s) - infliximab , medicine , dosing , crohn's disease , disease , crohn disease , dermatology , surgery , gastroenterology
Summary Anti‐tumour necrosis factor‐α therapy of Crohn's disease (CD) with infliximab has proved a major advance in the treatment of patients with difficult disease. We report our experience of the use of infliximab in a patient with recalcitrant vulval CD. The introduction of infliximab has improved disease control, although a search for an optimum remittive dosing schedule is ongoing.